Earning Analysis
Welcome to our in-depth analysis of Altimmune Inc(ALT) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Altimmune Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-06 | Pre-Market | -0.29 | -0.21 | +27.59 | 560.00 | 5.00K | +792.86 | +5.07 | +14.13 |
| FY2025Q2 | 2025-08-12 | Pre-Market | -0.32 | -0.27 | +15.62 | 560.00 | 5.00K | +792.86 | +7.10 | +7.40 |
| FY2025Q1 | 2025-05-13 | Pre-Market | -0.35 | -0.26 | +25.71 | 560.00 | 5.00K | +792.86 | -4.16 | -7.15 |
| FY2024Q4 | 2025-02-27 | Pre-Market | -0.34 | -0.33 | +2.94 | 150.00K | 5.00K | -96.67 | +8.08 | -3.70 |
| FY2024Q2 | 2024-08-08 | Pre-Market | -0.34 | -0.35 | +2.94 | 620.00 | 5.00K | +706.45 | +15.09 | +12.36 |
| FY2024Q1 | 2024-05-09 | - | -0.36 | -0.34 | +5.56 | - | 5.00K | - | +7.82 | +23.88 |
| FY2023Q4 | 2024-03-27 | - | -0.35 | -0.33 | +5.71 | 2.14K | 37.00K | +1628.97 | +2.77 | +7.40 |
| FY2023Q3 | 2023-11-07 | - | -0.40 | -0.39 | +2.50 | 860.00 | 362.00K | +41993.02 | +1.12 | -8.61 |
| FY2023Q2 | 2023-08-10 | - | -0.44 | -0.32 | +27.27 | 3.00K | 6.00K | +100.00 | +3.05 | -7.80 |
| - | 2023-05-11 | - | -0.49 | -0.40 | +18.37 | - | - | - | +7.03 | -7.63 |
ALT Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Altimmune Inc reported performance for FY2025Q3, announced on 2025-11-06. The company achieved an EPS of -0.21, compared to analyst estimates of -0.29 by 27.59% . Revenue for the quarter reached 5.00K compared to expectations of 560.00 by 792.86% .
The stock price reacted with a 5.07% one-day change and a 14.13% five-day change following the earnings release. These movements reflect market reaction in Altimmune Inc growth trajectory and strategic initiatives.
ALT Earnings Forecast
Looking ahead, Altimmune Inc(ALT) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 560.00 and an EPS of -0.25.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by -0%. For the upcoming Q4 2025, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a 40.48% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Altimmune Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between ALT's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q4 2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+40.48%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:5.10K
--
EPS Estimate-Annual FY 2025:-1.13
—
Stock Price5.31
ALT Revenue and EPS Performance: A Historical Perspective
Altimmune Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-06,Pre-Market):
EPS: -0.21 (Actual) vs.-0.29 (Estimate) (27.59%)
Revenue: 5.00K (Actual) vs. 560.00 (Estimate) (792.86%)
Price Reaction: 5.07%(1-Day), 14.13%(5-Day)
FY2025Q2 (2025-08-12,Pre-Market):
EPS: -0.27 (Actual) vs.-0.32 (Estimate) (15.62%)
Revenue: 5.00K (Actual) vs. 560.00 (Estimate) (792.86%)
Price Reaction: 7.10%(1-Day), 7.40%(5-Day)
FY2025Q1 (2025-05-13,Pre-Market):
EPS: -0.26 (Actual) vs.-0.35 (Estimate) (25.71%)
Revenue: 5.00K (Actual) vs. 560.00 (Estimate) (792.86%)
Price Reaction: -4.16%(1-Day), -7.15%(5-Day)
Earnings Reaction
The chart below shows how ALT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ALT sees a -0.78% change in stock price 10 days leading up to the earnings, and a -6.46% change 10 days following the report. On the earnings day itself, the stock moves by +5.30%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 4.31% on the day following the earnings release and then changed by 13.45% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Altimmune Inc (ALT) Q3 2025 Earnings Call Summary
Positive
2025-11-06
The earnings call summary reveals strong financial health with increased cash reserves and reduced net loss. Product development is progressing, with promising trials and strategic FDA interactions. The Q&A highlights optimism about innovative approaches, like AI-based biopsy readings, and differentiation in competitive markets. Despite some unclear responses, the overall sentiment is positive due to financial stability, strategic developments, and potential market differentiation.
Altimmune Inc (ALT) Q2 2025 Earnings Call Summary
Positive
2025-08-13
The earnings call summary and Q&A session reveal strong financial health with increased cash reserves and reduced losses. The company is optimistic about its trials and FDA interactions, planning strategic developments. Decreased R&D expenses and confidence in trial endpoints are positive indicators. However, some management responses were vague, which slightly tempers enthusiasm. Overall, the financial and strategic outlook is promising, suggesting a positive stock movement.
Altimmune Inc (ALT) Q1 2025 Earnings Call Summary
Neutral
2025-05-13
The earnings call reveals both positive and negative factors. Financial management has improved, with reduced net loss and increased cash position. However, reliance on external financing and competitive pressures in NASH, AUD, and ALD present risks. The Q&A section shows management's optimism but lacks clarity on key metrics. The uncertain trial outcomes and economic factors add to the risks. Overall, the mixed signals suggest a neutral stock price movement, as positive cash flow improvements are offset by uncertainties in trial success and competitive market dynamics.
Altimmune Inc (ALT) Q4 2024 Earnings Call Summary
Negative
2025-02-27
The company's financial performance is concerning with a net loss of $95 million for 2024, increased R&D expenses, and supply chain challenges. The Q&A reveals uncertainties in FDA decisions and unclear management responses, particularly about Phase III design and timelines. Despite some positive aspects like cash runway and strategic plans, the overall sentiment is negative due to significant financial risks and uncertainties in clinical trial outcomes.
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Summary
Negative
2024-11-12
The earnings call reflects several concerns: increased net loss, ongoing financial challenges despite cash runway, and competitive pressures in a fast-moving market. While there is strategic development in the pipeline, uncertainties in regulatory approval and competitive landscape pose risks. Additionally, the lack of detailed guidance on new indications and study timelines adds to investor uncertainty. The Q&A session did not alleviate these concerns, as management provided limited specifics. Overall, these factors suggest a negative sentiment, likely leading to a stock price decline in the short term.
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Summary
Neutral
2024-08-10
The earnings call presents a mixed picture. Financial performance shows increased expenses and net loss, but cash reserves are projected to last until 2026. Product development is progressing well, with positive enrollment in trials and potential partnerships. However, concerns about supply chain issues and management's vague responses in the Q&A raise uncertainties. The lack of revenue and increased net loss are negatives, but the optimistic guidance on partnerships and trial progress balances the sentiment. Overall, the sentiment is neutral, with no strong indicators for significant stock movement in either direction.
People Also Watch
FAQ
What were the key highlights of ALT’s latest earnings report for FY2025Q3?
How did ALT’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for ALT for 2025/Q4?
How does ALT’s stock price correlate with earnings forecast revisions?
What should investors expect from ALT’s next earnings report?